Related Experiment Video
Updated: Mar 31, 2026
16:26
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
6.3K
Teneligliptin: a review in type 2 diabetes
1Springer, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand. demail@springer.com
Clinical Drug Investigation
|October 18, 2015
Summary
Teneligliptin, a DPP-4 inhibitor, effectively manages type 2 diabetes in adults. It improves glycemic control and is well-tolerated in monotherapy or combination treatments.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Type 2 diabetes mellitus (T2DM) is a global health concern requiring effective management strategies.
- Dipeptidyl peptidase-4 (DPP-4) inhibitors offer a therapeutic option for T2DM.
- Oral teneligliptin is a DPP-4 inhibitor approved for T2DM treatment.
Purpose of the Study:
- To review the pharmacology, efficacy, and tolerability of oral teneligliptin in adults with T2DM.
- To evaluate teneligliptin's role in glycemic control and safety profile.
Main Methods:
- Systematic review of placebo-controlled phase 2 and 3 trials.
- Analysis of short-term (12-16 weeks) and long-term (52 weeks) data.
- Inclusion of studies involving monotherapy and combination therapy with other antidiabetic agents.
Main Results:
- Teneligliptin (20 or 40 mg once daily) significantly improved glycemic control in T2DM patients.
- Effective in monotherapy and combination with metformin, glimepiride, or pioglitazone.
- Well-tolerated with mild adverse events; long-term safety profile remained consistent.
Conclusions:
- Teneligliptin is a viable treatment option for adults with T2DM inadequately controlled by diet and exercise or other antidiabetic drugs.
- Sustained glycemic control and favorable safety profile observed over 52 weeks.
- Further head-to-head trials are needed to establish its comparative position among antidiabetic agents.
More Related Videos
10:09Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets
Published on: May 11, 2015
10.2K
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
1.0K
Related Concept Videos
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:06Oral Hypoglycemic Agents: Glinides
945
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
945
01:23Dipeptidyl Peptidase 4 Inhibitors
1.0K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.0K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
946
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
946
01:15Diabetes: Management and Pharmacotherapy
1.4K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.4K
01:22Diabetes Mellitus: Type 2 and Gestational
5.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.5K